ENDP.Q Stock Overview
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Endo International plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0006 |
| 52 Week High | US$0.08 |
| 52 Week Low | US$0.000001 |
| Beta | 0.80 |
| 1 Month Change | 100.00% |
| 3 Month Change | 0% |
| 1 Year Change | -99.04% |
| 3 Year Change | -99.99% |
| 5 Year Change | -99.99% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Endo creditors looking at putting company up for sale through bankruptcy - Bloomberg
Aug 16Endo International sees 23% rise on 3x higher than normal volume
Aug 03Endo outperforms defying bankruptcy fears and generic entry
Jul 25Endo weighs bankruptcy filing without opioid settlement - WSJ
Jul 12Endo International cools off, giving back some of its 85% Tuesday gain
Jun 29Endo: Stick A Fork In It
May 10Endo: About As Bad As It Gets
Mar 07Endo: FDA Approves Generic Form Of Vasostrict Creating Headwind Into Next Year
Dec 16Endo: A Win In California But Equity Value Still A Question
Nov 02Endo International: Loses Vasostrict Trial
Aug 31Endo International: Hires Restructuring Advisor
Aug 20Endo International: All About Ongoing Litigation
Aug 07Endo: Appellate Court Denies Request To Postpone Damages Trial Might Be End O' The Road
Jul 15Endo International: Bankruptcy Seems Like The Only Practical Option
Jun 30Endo International wins FDA approval for Micafungin new formulation
Jun 17Endo International plc 2021 Q1 - Results - Earnings Call Presentation
May 07Radius Health partners with Endo unit for abaloparatide in Canada
Jan 05Shareholder Returns
| ENDP.Q | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -0.6% | 1.0% |
| 1Y | -99.0% | 10.6% | 21.9% |
Return vs Industry: ENDP.Q underperformed the US Pharmaceuticals industry which returned 13.2% over the past year.
Return vs Market: ENDP.Q underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| ENDP.Q volatility | |
|---|---|
| ENDP.Q Average Weekly Movement | 205.6% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ENDP.Q's share price has been volatile over the past 3 months.
Volatility Over Time: ENDP.Q's weekly volatility has increased from 124% to 206% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1920 | 2,931 | Blaise Coleman | www.endo.com |
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The company offers branded pharmaceuticals, including XIAFLEX to treat adult patients with Dupuytren’s contracture and Peyronie’s disease; SUPPRELIN LA to treat central precocious puberty in children; AVEED to treat hypogonadism; NASCOBAL nasal spray to treat vitamin B12 deficiency; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET for pain management; TESTOPEL, an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; and EDEX to treat erectile dysfunction, as well as opioid products to treat pain associated with post-herpetic neuralgia.
Endo International plc Fundamentals Summary
| ENDP.Q fundamental statistics | |
|---|---|
| Market cap | US$141.13k |
| Earnings (TTM) | -US$2.45b |
| Revenue (TTM) | US$2.01b |
0.0x
P/S Ratio0.0x
P/E RatioIs ENDP.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ENDP.Q income statement (TTM) | |
|---|---|
| Revenue | US$2.01b |
| Cost of Revenue | US$941.90m |
| Gross Profit | US$1.07b |
| Other Expenses | US$3.52b |
| Earnings | -US$2.45b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -10.41 |
| Gross Margin | 53.17% |
| Net Profit Margin | -121.69% |
| Debt/Equity Ratio | -123.5% |
How did ENDP.Q perform over the long term?
See historical performance and comparison